Akebia Therapeutics shares are trading lower after the company announced the late filing of its Q2 earnings and Form 10Q but reaffirmed its FY23 net product revenue guidance.
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has announced a delay in the filing of its Q2 earnings and Form 10Q. However, the company has reaffirmed its FY23 net product revenue guidance. This news has led to a decrease in the company's share price.
August 11, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akebia Therapeutics' shares are trading lower following the announcement of a delay in the filing of its Q2 earnings and Form 10Q. The company has, however, reaffirmed its FY23 net product revenue guidance.
The delay in the filing of Q2 earnings and Form 10Q is generally perceived negatively by the market, leading to a decrease in the company's share price. However, the reaffirmation of the FY23 net product revenue guidance might mitigate the negative impact to some extent in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100